Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 28;11(9):2475. doi: 10.3390/jcm11092475

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

FDG-PET/CT images before (A) and during (B) therapy with osimertinib + erdafitinib in a patient with an EGFR mutated aNSCLC and FGFR3-TACC3 fusion following progression on osimertinib. Shrinkage of a retro-caval lymph node with a reduction in FDG-avidity, stable lung metastasis with a reduction in FDG-avidity, calcification of a D3 lytic bone metastasis with a reduction in FDG-avidity (gray and black arrows). Abbreviations: aNSCLC—advanced non-small cell lung cancer; EGFR—epidermal growth factor receptor; FDG—fluorodeoxyglucose; FGFR3-TACC3—fibroblast growth factor receptor 3-transforming acidic coiled-coil-containing protein 3; PET/CT—positron emission tomography/computer tomography.